<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1143</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2019-10-48-51</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Review of the Russian pharmaceutical market: results of the 1st half of 2019</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalinina</surname><given-names>Nadezhda</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">Remedium</aff><pub-date date-type="epub" iso-8601-date="2019-12-10" publication-format="electronic"><day>10</day><month>12</month><year>2019</year></pub-date><issue>10</issue><fpage>48</fpage><lpage>51</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2019,</copyright-statement><copyright-year>2019</copyright-year></permissions><abstract>At the end of the 1st half of 2019, the Russian pharmaceutical market significantly increased in value terms, reaching 609.0 bil. rubles at purchase prices. Even though the commercial sector accounts for about 70% of this volume, the sales grew significantly mainly due to an increase in government purchases under the federal and regional special-purpose health programmes (in the pharmaceutical benefits segment).</abstract><kwd-group xml:lang="en"><kwd>Russian pharmaceutical market</kwd><kwd>retail pharmaceutical market</kwd><kwd>hospital pharmaceutical market</kwd><kwd>cost-intensive nosologies (VZN)</kwd><kwd>trends</kwd><kwd>leaders</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>российский фармацевтический рынок</kwd><kwd>розничный фармацевтический рынок</kwd><kwd>госпитальный фармацевтический рынок</kwd><kwd>ВЗН</kwd><kwd>тренды</kwd><kwd>лидеры</kwd></kwd-group></article-meta></front><body></body><back/></article>
